Revised clinical practice guidelines for diagnosing, classifying, and treating allergic bronchopulmonary aspergillosis/mycoses: a Delphi statement from the ISHAM-ABPA working group - Archive ouverte HAL
Article Dans Une Revue European Respiratory Journal Année : 2024

Revised clinical practice guidelines for diagnosing, classifying, and treating allergic bronchopulmonary aspergillosis/mycoses: a Delphi statement from the ISHAM-ABPA working group

David W Denning
Arunaloke Chakrabarti
  • Fonction : Auteur
  • PersonId : 1104791
Koichiro Asano
  • Fonction : Auteur
Sanjay Chotirmall
Cendrine Godet
Iain Page
  • Fonction : Auteur
R Dhar
  • Fonction : Auteur
Geethu Joe
  • Fonction : Auteur
Uma Maheswari Krishnaswamy
  • Fonction : Auteur
Venkata Nagarjuna Maturu
  • Fonction : Auteur
A Nath
  • Fonction : Auteur
Dharmesh Patel
  • Fonction : Auteur
Jayanthi Savio
  • Fonction : Auteur
Puneet Saxena
  • Fonction : Auteur
Rajeev Soman
  • Fonction : Auteur
Balamugesh Thangakunam
  • Fonction : Auteur
Felix Bongomin
Richard Moss
  • Fonction : Auteur
Alessandro C Pasqualotto
  • Fonction : Auteur
  • PersonId : 1132504

Résumé

BACKGROUND: The ISHAM working group proposed recommendations for managing allergic bronchopulmonary aspergillosis (ABPA) nearly a decade ago. There is a need to update these recommendations due to advances in diagnostics and therapeutics. METHODS: An international expert group was convened to develop guidelines for managing ABPA (caused by Aspergillus spp.) and allergic bronchopulmonary mycosis (ABPM, fungi other than Aspergillus spp.) in adults and children using a modified Delphi method (two online rounds and one in-person meeting). We defined consensus as ≥70% agreement or disagreement. The terms "recommend" and "suggest" are used when the consensus was ≥70% and <70%. RESULTS: We recommend screening for A. fumigatus sensitization using fungus-specific IgE in all newly diagnosed adult asthmatics at tertiary care but only difficult-to-treat asthmatic children. We recommend diagnosing ABPA in those with predisposing conditions or compatible clinico-radiological presentation, with a mandatory demonstration of fungal sensitization and serum total IgE ≥500 IU·mL(-1) and two of the following: fungal-specific IgG, peripheral blood eosinophilia, or suggestive imaging. ABPM is considered in those with an ABPA-like presentation but normal A. fumigatus-IgE. Additionally, diagnosing ABPM requires repeated growth of the causative fungus from sputum.We do not routinely recommend treating asymptomatic ABPA patients. We recommend oral prednisolone or itraconazole monotherapy for treating acute ABPA (newly diagnosed or exacerbation), with prednisolone and itraconazole combination only for treating recurrent ABPA exacerbations. We have devised an objective multidimensional criterion to assess treatment response. CONCLUSION: We have framed consensus guidelines for diagnosing, classifying, and treating ABPA(M) for patient care and research.
Fichier principal
Vignette du fichier
2400061.full.pdf (2.14 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-04512650 , version 1 (24-09-2024)

Licence

Identifiants

Citer

Ritesh Agarwal, Inderpaul Singh Sehgal, Valliappan Muthu, David W Denning, Arunaloke Chakrabarti, et al.. Revised clinical practice guidelines for diagnosing, classifying, and treating allergic bronchopulmonary aspergillosis/mycoses: a Delphi statement from the ISHAM-ABPA working group. European Respiratory Journal, 2024, European Respiratory Journal, pp.2400061. ⟨10.1183/13993003.00061-2024⟩. ⟨hal-04512650⟩
62 Consultations
12 Téléchargements

Altmetric

Partager

More